The share price of Lincoln Pharmaceuticals Limited (LPL) reached an all-time high of ₹833 on Tuesday, December 4, 2024, on the NSE. The stock’s performance, bolstered by strong foreign institutional investor (FII) interest. FIIs increased their holdings from 3.95% in June 2024 to 5.19% in September 2024.
LPL’s financial performance has been nothing short of exemplary. The company reported a record net profit exceeding ₹100 crore in FY24—the highest in the last decade. Notably, Lincoln Pharmaceuticals has maintained a remarkable trajectory of profit growth for ten consecutive years, from FY13 to FY23.
16 companies out of the 4,200+ listed in India have achieved such consistency, underscoring LPL’s financial discipline. Over the ten-year period, LPL delivered a Compound Annual Growth Rate (CAGR) of:
Lincoln Pharmaceuticals has a well-diversified export portfolio, serving over 60 countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. The company’s strategic focus on global markets is evident from its recent entry into the Canadian market and approvals from regulatory bodies like TGA – Australia and EU GMP.
Additionally, LPL is actively registering products from its Cephalosporin plant in Mehsana, Gujarat, aligning with its revenue target of ₹750 crore for FY26. These efforts highlight its commitment to scaling operations while maintaining quality standards.
Lincoln Pharmaceuticals has negligible long-term borrowings, which provides a solid foundation for sustainable growth. Its prudent financial management has contributed to its robust market position.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
